Drug intelligence / Profile preview

JUVÉDERM VOLBELLA XC

Development stage
Unknown
Lead developer
Allergan
Modality
Small Molecules
Administration
Intradermal, Subcutaneous
01

Overview

JUVÉDERM VOLBELLA XC is a sterile, biodegradable, non-pyrogenic gel implant classified as an injectable dermal filler. It consists of cross-linked hyaluronic acid (HA) produced by Streptococcus species of bacteria at a concentration of 15 mg/mL and includes 0.3% lidocaine as a local anesthetic to reduce injection discomfort. The product is designed for injection into the lips for lip augmentation, correction of perioral rhytids (lines around the mouth), and improvement of infraorbital hollowing (undereye hollows) in adults over age 21. Its mechanism involves temporarily adding volume or fullness to targeted facial areas by integrating into the tissue matrix and attracting water molecules due to HA’s hydrophilic properties. Results typically last up to one year[1][2][3][4][5][6][7].

Brand names
JUVÉDERM VOLBELLA XCJUVEDERM VOLBELLA with Lidocaine
Other names
Juvederm VolbellaJuvederm Volbella with Lidocaine
02

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on JUVÉDERM VOLBELLA XC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on JUVÉDERM VOLBELLA XC.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call